Medical Design Technology, April 4, 2016. The National Center for Health Research expresses that Advancing Breakthrough Devices for Patients Act of 2015 encourages companies to get medical products on the market quickly as opposed to focusing on patient safety and product efficiency.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Possible Drug Risks Buried in Delayed FDA ‘Watch Lists’
Medscape Medical News, March 29, 2016. Dr Diana Zuckerman explains that publication delays of drug watch lists illustrate how the FDA caters more to drug manufacturers than patients.
Read More »Can an Implant Stop Heroin Addiction?
The Daily Beast, March 27, 2016. Tracy Rupp told the advisory committee at the FDA that she was “disappointed to conclude” that the evidence wasn’t enough for her to endorse the opioid addition treatment. “While we all desperately want new treatments for opioid abuse, we have to be sure they are safe and effective,” she said.
Read More »Senate Approves FDA’s ‘Breakthrough Pathway’ for Medical Devices’
DOTmed.com, March 23, 2016. Diana Zuckerman, president of the National Center for Health Research, wrote on behalf of the watchdog group that it was “concerned that the focus of these bills is on getting medical products to market more quickly, instead of making sure they are safe and effective.”
Read More »US Device Industry and FDA “Colluded” on Legislation to Weaken Regulatory Oversight
The BMJ, December 17, 2005. Dr. Diana Zuckerman from The National Center for Health Research shared, “There’s a world of difference between talking about approval standards in general and crafting specific legislative language. It is outrageous that FDA officials and regulated industry are sitting down to craft legislative language to give to congressional staff.”
Read More »